Preferred Label : purines;
MeSH definition : A series of heterocyclic compounds that are variously substituted in nature and are
known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic
acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the
metabolic end product of purine metabolism.;
Wikipedia automatic translation : Purin;
Wikipedia link : https://en.wikipedia.org/wiki/Purin;
Codes EINECS : 204-421-2;
Is substance : O;
Origin ID : D011687;
UMLS CUI : C0034140;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- 10,13-dimethyl-17-(2-(6-sulfanylidene-3H-purin-9-yl)acetyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta(a)phenanthren-3-one [MeSH Supplementary Concept]
- 3MB-PP1 [MeSH Supplementary Concept]
- AEE 788 [MeSH Supplementary Concept]
- AM-0902 [MeSH Supplementary Concept]
- AP23236 [MeSH Supplementary Concept]
- AZD7648 [MeSH Supplementary Concept]
- CAL-130 [MeSH Supplementary Concept]
- CB002 [MeSH Supplementary Concept]
- CC-359 [MeSH Supplementary Concept]
- CVT 313 [MeSH Supplementary Concept]
- GNE-293 [MeSH Supplementary Concept]
- HOE 602 [MeSH Supplementary Concept]
- HOE 961 [MeSH Supplementary Concept]
- INU-152 [MeSH Supplementary Concept]
- KI 7 [MeSH Supplementary Concept]
- NU6102 [MeSH Supplementary Concept]
- PP242 [MeSH Supplementary Concept]
- S 2242 [MeSH Supplementary Concept]
- SB2602 [MeSH Supplementary Concept]
- SK 1899 [MeSH Supplementary Concept]
- SKLB188 [MeSH Supplementary Concept]
- SR-2890 [MeSH Supplementary Concept]
- SR-3029 [MeSH Supplementary Concept]
- SV-030 [MeSH Supplementary Concept]
- TAS0728 [MeSH Supplementary Concept]
- VER6947 [MeSH Supplementary Concept]
- VER7835 [MeSH Supplementary Concept]
- VS-5584 [MeSH Supplementary Concept]
- WYE-354 [MeSH Supplementary Concept]
- WZ16 [MeSH Supplementary Concept]
- purine [MeSH Supplementary Concept]
See also (suggested by CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A series of heterocyclic compounds that are variously substituted in nature and are
known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic
acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the
metabolic end product of purine metabolism.
2021
false
false
false
France
French
administration, oral
baricitinib
risk management
pregnancy
baricitinib
guidelines for drug use
breast feeding
patients guideline
dermatitis, atopic
arthritis, rheumatoid
baricitinib
Janus Kinase Inhibitors
Janus Kinase Inhibitors
drug monitoring
deep vein thrombosis
pulmonary embolism
cholesterol, HDL
cholesterol, LDL
Infections
vaccines, attenuated
venous thrombosis
azetidines
sulfonamides
purines
pyrazoles
azetidines
sulfonamides
purines
pyrazoles
---
https://www.has-sante.fr/jcms/p_3229924/fr/kisqali
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
Ribociclib Succinate
antineoplastic combined chemotherapy protocols
Fulvestrant/Ribociclib Regimen
Fulvestrant
antineoplastic agents
breast neoplasms
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
protein kinase inhibitors
evaluation of the transparency committee
aminopyridines
purines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
duvelisib
duvelisib
drug approval
europe
duvelisib
antineoplastic agents
antineoplastic agents
lymphoma, follicular
leukemia, lymphocytic, chronic, B-Cell
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Refractory Follicular Lymphoma
administration, oral
drug monitoring
phosphatidylinositol 3-Kinase
adult
aged
drug interactions
pregnancy
breast feeding
PIK3CG protein, human
Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform
Copiktra
isoquinolines
purines
isoquinolines
purines
class ib phosphatidylinositol 3-Kinase
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---
https://www.has-sante.fr/jcms/p_3199713/fr/kisqali
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
administration, oral
ribociclib
ribociclib
antineoplastic combined chemotherapy protocols
breast neoplasms
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
antineoplastic agents
protein kinase inhibitors
treatment outcome
aminopyridines
purines
---
https://www.has-sante.fr/jcms/p_3191487/fr/rapiscan
2020
false
false
false
France
regadenoson
fractional flow reserve, myocardial
diagnostic uses of chemicals
regadenoson
insurance, health, reimbursement
coronary stenosis
coronary angiography
evaluation of the transparency committee
purines
pyrazoles
---
https://www.has-sante.fr/jcms/p_3097597/fr/kisqali
2020
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
ribociclib
ribociclib
Fulvestrant/Ribociclib Regimen
Fulvestrant
postmenopause
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
breast neoplasms
survival analysis
insurance, health, reimbursement
antineoplastic agents
evaluation of the transparency committee
aminopyridines
purines
---
https://www.has-sante.fr/jcms/p_3103868/fr/kisqali
2019
false
false
false
France
breast neoplasms
antineoplastic combined chemotherapy protocols
ribociclib
ribociclib
antineoplastic agents
aromatase inhibitors
Letrozole
Anastrozole
adult
evaluation of the transparency committee
aminopyridines
purines
---
https://www.has-sante.fr/jcms/c_2827573/fr/kisqali
2018
false
false
false
France
French
treatment outcome
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Stage IV Breast Cancer AJCC v6 and v7
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
HER2/Neu Negative
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
antineoplastic combined chemotherapy protocols
adult
aged
ribociclib
evaluation of the transparency committee
guidelines for drug use
aminopyridines
purines
aminopyridines
purines
---
https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig-idelalisib-antineoplasique
https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig
2018
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
Rituximab
continuity of patient care
pneumonia, pneumocystis
neutropenia
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---
Summary Safety Review - Zydelig (idelalisib) - Assessing the potential risk of serious
infections
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/zydelig-fra.php
2017
false
false
false
Canada
French
English
idelalisib
idelalisib
canada
administration, oral
antineoplastic agents
risk assessment
drug evaluation
Infections
Infections
pharmacovigilance note
purines
quinazolinones
---
https://www.ema.europa.eu/medicines/human/EPAR/Kisqali
2017
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ribociclib
ribociclib
neoplasm metastasis
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Locally advanced breast cancer
breast neoplasms
postmenopause
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
Cyclin-Dependent kinase 4
Cyclin-Dependent kinase 6
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
aged
drug interactions
drug evaluation, preclinical
ribociclib
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
Fulvestrant/Ribociclib Regimen
aminopyridines
purines
aminopyridines
purines
---
ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58118a-fra.php
2016
false
false
false
Canada
French
English
survival analysis
idelalisib
idelalisib
leukemia, lymphocytic, chronic, B-Cell
risk assessment
antineoplastic agents
cause of death
Infections
antineoplastic combined chemotherapy protocols
Rituximab
continuity of patient care
pneumonia, pneumocystis
sepsis
cytomegalovirus infections
Chemotherapy-Induced febrile neutropenia
pharmacovigilance note
lymphoma, Non-Hodgkin
Indolent Non-Hodgkin Lymphoma
purines
quinazolinones
---
http://www.has-sante.fr/portail/jcms/c_2628549/fr/zydelig
2016
false
false
false
France
French
treatment outcome
purines
quinazolinones
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
evaluation of the transparency committee
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
chromosome 17 deletion
phosphatidylinositol 3-Kinases
Smith-Magenis syndrome
chromosome deletion
chromosomes, human, pair 17
Phosphoinositide-3 Kinase Inhibitors
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/57590a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
canada
antineoplastic combined chemotherapy protocols
antineoplastic agents
idelalisib
early termination of clinical trials
idelalisib
purines
quinazolinones
---
http://www.has-sante.fr/portail/jcms/c_2047021/fr/zydelig-idelalisib-inhibiteur-de-kinase
2015
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---
https://www.ema.europa.eu/medicines/human/EPAR/Zydelig
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
purines
purines
quinazolinones
quinazolinones
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
tablets
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
drug interactions
pregnancy
breast feeding
idelalisib
drug evaluation, preclinical
idelalisib
idelalisib
Idelalisib/Rituximab Regimen
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors
---